Cerus(NASDAQ) CERS

Market Cap$473.58M

Since IPO (1997)-81%

5 Year-62%

1 Year+90%

1 Month-25%

$2.35

+1.29%

+0.03Today

After hours$2.35-$0.01 (-0.21%)

Cerus last closing stock price
Metric	Price	Date
Last close	USD 2.35	2026-08-07

Cerus stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9.3%	USD 2.15	2026-07-31
1 month	-25.16%	USD 3.14	2026-07-08
3 month	-9.96%	USD 2.61	2026-05-08
Year to date	+14.08%	USD 2.06	2025-12-31
1 year	+89.52%	USD 1.24	2025-08-07
3 year	+14.91%	USD 2.05	2023-08-08
5 year	-62.28%	USD 6.23	2021-08-06
Since inception	-80.62%	USD 12.13	1997-01-31

Cerus Financials at a Glance

Market Cap

$473.58M

Revenue (TTM)

$221.55M

Net Income (TTM)

-$6.78M

EPS (TTM)

-$0.03

P/E Ratio

-67.92

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$2.35

Volume

3,484,714

Open

$2.30

Price

$2.35

Volume

3,484,714

Open

$2.30

Previous Close

$2.35

Daily Range

$2.30 - $2.43

52-Week Range

$1.15 - $3.47

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$2.35

Volume

3,484,714

Open

$2.30

Previous Close

$2.35

Daily Range

$2.30 - $2.43

52-Week Range

$1.15 - $3.47

Estimated Earnings Date

Nov 5, 2026

CERS News

Page 1

CERS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cerus

Cerus makes products that clean donated blood for patients. Its systems stop germs from growing in blood components. This helps hospitals provide safer transfusions to people.

The Blood Safety Kit

Platelet and Plasma Systems: Disposable kits and light devices used to reduce pathogens in blood components; sold across North America, Europe, and the Middle East.
Fibrinogen Complex: Specialized blood product used to treat and control massive bleeding in hospital settings.
Illumination Devices: Hardware that uses ultraviolet light to activate the blood cleaning process.
Red Blood Cell System: Technology currently in clinical development to expand the pathogen-reduction platform to red blood cell transfusions.

Growth and Partnership Moves

Entered a manufacturing agreement with Fresenius Kabi AG in May 2022 to produce disposable sets through 2031.
Signed a new contract with BARDA in September 2024 for up to $32 million to develop red blood cell treatments.
Expanded a U.S. Department of Defense agreement in July 2025 to increase trauma treatment funding to $25 million.
Established a joint venture with Shandong Zhongbaokang Medical Implements in 2021 to enter the Chinese medical market.

Global Reach and Innovation

Cerus operates a specialized distribution network that serves blood banks and hospitals across North America, Europe, and Latin America. The company leverages long-term government contracts to fund the high costs of clinical trials for new medical devices.

Financial Performance Trajectory

Revenue reached $59.9 million in Q1 2026, up 38.5% from $43.2 million in Q1 2025.
Gross profit was $34.1 million in Q1 2026, up 34.2% from $25.4 million in Q1 2025.
Net loss narrowed to $1.6 million in Q1 2026, an improvement from $7.7 million in Q1 2025.
Free cash flow hit negative $3.3 million in Q1 2026, worsening from negative $956,000 in Q1 2025.
Operating income improved to negative $354,000 in Q1 2026, up from a $11.5 million loss in Q1 2025.

The Final Word

Cerus has evolved from a development-stage company into a commercial provider of essential blood safety technology. Its business model relies on expanding regulatory approvals and deep integration with national blood supply systems.

AI Generated • May 5, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

275

CEO

Obi Greenman

Website

www.cerus.com

Headquarters

Concord, CA 94520, US

CERS Financials

Key Financial Metrics (TTM)

Gross Margin

52.05%

Operating Margin

-0.73%

Net Income Margin

-3.06%

Return on Equity

-10.31%

Return on Capital

-5.39%

Return on Assets

-3.31%

Earnings Yield

-1.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$473.58M

Shares Outstanding

201.53M

Volume

3.48M

Avg. Volume

2.72M

Financials (TTM)

Gross Profit

$115.32M

Operating Income

-$1.62M

EBITDA

$2.91M

Operating Cash Flow

$2.42M

Capital Expenditure

-$4.25M

Free Cash Flow

-$1.83M

Cash & ST Invst.

$56.26M

Total Debt

$76.80M

Cerus Performance Analysis

Cerus annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 162,048,000	23.8%
2023	2023-12-31	USD 156,367,000	-3.5%
2024	2024-12-31	USD 180,270,000	15.3%
2025	2025-12-31	USD 206,133,000	14.3%

Cerus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	0.5%
Q4	2025-12-31	9.6%
Q1	2026-03-31	-7.1%
Q2	2026-06-30	7.0%

Cerus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.24	-23.7%
2023	2023-12-31	USD -0.21	-14.2%
2024	2024-12-31	USD -0.11	-45.5%
2025	2025-12-31	USD -0.08	-27.6%

Cerus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	99.7%
Q4	2025-12-31	-11300.0%
Q1	2026-03-31	12.3%
Q2	2026-06-30	-47.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$57.44M

+9.5%

Gross Profit

$29.53M

+1.9%

Gross Margin

51.41%

N/A

Market Cap

$473.58M

N/A

Market Cap/Employee

$1.72M

N/A

Employees

275

N/A

Net Income

-$2.94M

+48.5%

EBITDA

-$712.00K

+77.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$56.26M

-27.9%

Total Debt

$76.80M

-22.3%

Accounts Receivable

$30.98M

-1.3%

Inventory

$65.81M

+20.7%

Long Term Debt

$43.46M

-36.2%

Short Term Debt

$33.34M

+8.5%

Return on Assets

-3.31%

N/A

Return on Invested Capital

-1.35%

N/A

Free Cash Flow

-$3.53M

-20.9%

Operating Cash Flow

-$2.66M

-8.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NPCENeuroPace, Inc.

NPCENeuroPace, Inc.$14.83+6.69%

SGHTSight Sciences, Inc.

SGHTSight Sciences, Inc.$7.47+5.36%

MASS908 Devices Inc.

MASS908 Devices Inc.$8.88+6.99%

TKNOAlpha Teknova, Inc.

TKNOAlpha Teknova, Inc.$6.46-1.07%

SENSSenseonics Holdings, Inc.

SENSSenseonics Holdings, Inc.$7.02+36.31%

RXSTRxSight, Inc.

RXSTRxSight, Inc.$6.26+2.96%

QTRXQuanterix Corporation

QTRXQuanterix Corporation$4.03+5.22%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$133.11+0.16%

TTDThe Trade Desk

TTDThe Trade Desk$13.80-0.22%

NVDANvidia

NVDANvidia$223.96+0.02%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.76+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.11+0.06%

PLTRPalantir Technologies

PLTRPalantir Technologies$172.01+0.10%

INTCIntel

INTCIntel$101.65+0.02%

Questions About CERS

What is the current price of Cerus?

Cerus is trading at $2.35 per share.

What is the 52-week range for Cerus?

Over the past 52 weeks, Cerus has traded between $1.15 and $3.47.

How much debt does Cerus have?

As of the most recent reporting period, Cerus reported total debt of $76.80M.

How much cash does Cerus have on hand?

Cerus reported $17.98M in cash and cash equivalents in its most recent financial results.

What is Cerus’s dividend yield?

Cerus does not currently have a dividend yield.

Cerus(NASDAQ) CERS

Cerus Financials at a Glance

CERS News

Here's Why Cerus Corporation Stock Popped Today

Here's Why Cerus Corporation Stock Is Surging Today

Here's Why Cerus Corporation Stock Popped Today

Here's Why Cerus Corporation Rose as Much as 23.6% Today

Why Cerus Corporation Stock Marched Higher Today

Here's Why Cerus Corporation Rose as Much as 17.4% Today

Here's Why Cerus Corporation Rose as Much as 16.3% Today

Here's Why Cerus Corporation Stock Is Tanking Today

CERS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cerus

The Blood Safety Kit

Growth and Partnership Moves

Global Reach and Innovation

Financial Performance Trajectory

The Final Word

CERS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cerus Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CERS

What is the current price of Cerus?

What is the 52-week range for Cerus?

How much debt does Cerus have?

How much cash does Cerus have on hand?

What is Cerus’s dividend yield?

Premium Investing Services